PMID- 35631344
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 15
IP  - 5
DP  - 2022 Apr 22
TI  - Possible Association between the Use of Proton Pump Inhibitors and H(2) Receptor 
      Antagonists, and Esophageal Cancer: A Nested Case-Control Study Using a Korean 
      National Health Screening Cohort.
LID - 10.3390/ph15050517 [doi]
LID - 517
AB  - Although safety concerns regarding proton pump inhibitor (PPI)/H2-receptor 
      antagonists (H2RA) in the incident esophageal cancer have been raised, the 
      Asian-based report is unclear. We investigated the estimated likelihood of 
      incident esophageal cancer-its mortality depending on prior history of PPI/H2RA 
      use-and gastroesophageal reflux disease (GERD) in Koreans. Using the Korean 
      National Health Insurance Service-Health Screening Cohort data (2002-2015), a 
      case-control study was retrospectively conducted, including 811 patients with 
      incident esophageal cancer and 3244 controls matched with sex, age, income, and 
      residence. Propensity score overlap weighting was adjusted to balance the 
      baseline covariates. Overlap propensity score-weighted logistic regression 
      analyses were assessed to determine associations of the prior exposure of 
      PPI/H2RA (current vs. past) and the medication duration (<30-, 30-90-, vs. 
      >/=90-days) with incident esophageal cancer and its mortality among the total 
      participants or those with/without the GERD episodes, after adjusting for 
      multiple covariates including PPI/H2RA. The current exposure to either PPI or 
      H2RA showed higher odds for incident esophageal cancer than the nonuser group 
      ([13.23; 95%CI 10.25-17.06] and [4.34; 95%CI 3.67-5.14], respectively), 
      especially in all adults over the age of 40 years without GERD. Both current and 
      past exposures to PPI showed a decreased probability of mortality compared with 
      those of the nonuser group ([0.62; 95%CI 0.45-0.86] and [0.41; 95%CI 0.25-0.67], 
      respectively). However, current or past exposure to H2RA harbored the mutually 
      different likelihoods for mortality depending on the presence of GERD and old 
      age. This study carefully speculates on the possible link between PPI/H2RA and 
      incident esophageal cancer in the Korean population. Mortality appears to be 
      affected by certain risk factors depending on drug types, exposure history, old 
      age, and the presence of GERD.
FAU - Choi, Hyo Geun
AU  - Choi HG
AUID- ORCID: 0000-0003-1655-9549
AD  - Department of Otorhinolaryngology-Head & Neck Surgery, Hallym University Sacred 
      Heart Hospital, Hallym University College of Medicine, Anyang 14068, Korea.
FAU - Lee, Hong Kyu
AU  - Lee HK
AD  - Department of Thoracic and Cardiovascular Surgery, Hallym University Sacred Heart 
      Hospital, Hallym University College of Medicine, Anyang 14068, Korea.
FAU - Kang, Ho Suk
AU  - Kang HS
AD  - Division of Gastroenterology, Department of Internal Medicine, Hallym University 
      Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, 
      Korea.
FAU - Lim, Hyun
AU  - Lim H
AD  - Division of Gastroenterology, Department of Internal Medicine, Hallym University 
      Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, 
      Korea.
FAU - Kim, Joo-Hee
AU  - Kim JH
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of 
      Medicine, Hallym University Sacred Heart Hospital, Hallym University College of 
      Medicine, Anyang 14068, Korea.
FAU - Kim, Ji Hee
AU  - Kim JH
AUID- ORCID: 0000-0001-6937-8093
AD  - Department of Neurosurgery, Hallym University Sacred Heart Hospital, Hallym 
      University College of Medicine, Anyang 14068, Korea.
FAU - Kim, Nan Young
AU  - Kim NY
AUID- ORCID: 0000-0001-9245-8657
AD  - Hallym Institute of Translational Genomics and Bioinformatics, Hallym University 
      Medical Center, Anyang 14068, Korea.
FAU - Cho, Seong-Jin
AU  - Cho SJ
AD  - Department of Pathology, Kangdong Sacred Heart Hospital, Hallym University 
      College of Medicine, Seoul 05355, Korea.
FAU - Nam, Eun Sook
AU  - Nam ES
AD  - Department of Pathology, Kangdong Sacred Heart Hospital, Hallym University 
      College of Medicine, Seoul 05355, Korea.
FAU - Min, Kyueng-Whan
AU  - Min KW
AUID- ORCID: 0000-0002-4757-9211
AD  - Department of Pathology, Hanyang University Guri Hospital, Hanyang University 
      College of Medicine, Guri 11923, Korea.
FAU - Kwon, Mi Jung
AU  - Kwon MJ
AD  - Department of Pathology, Hallym University Sacred Heart Hospital, Hallym 
      University College of Medicine, Anyang 14068, Korea.
LA  - eng
GR  - NRF-2021-R1C1C100498611 to HGC/National Research Foundation of Korea/
GR  - NRF-2021R1G1A1093593 to HSK/National Research Foundation of Korea/
GR  - NRF-2019R1C1C100446312 to MJK/National Research Foundation (NRF) of Korea from 
      the Korean Ministry of Science and ICT/
PT  - Journal Article
DEP - 20220422
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC9146181
OTO - NOTNLM
OT  - H2-receptor antagonist
OT  - esophageal cancer
OT  - mortality
OT  - nationwide health insurance research database
OT  - nested case-control study
OT  - proton pump inhibitor
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/29 06:00
MHDA- 2022/05/29 06:01
PMCR- 2022/04/22
CRDT- 2022/05/28 01:38
PHST- 2022/03/21 00:00 [received]
PHST- 2022/04/19 00:00 [revised]
PHST- 2022/04/21 00:00 [accepted]
PHST- 2022/05/28 01:38 [entrez]
PHST- 2022/05/29 06:00 [pubmed]
PHST- 2022/05/29 06:01 [medline]
PHST- 2022/04/22 00:00 [pmc-release]
AID - ph15050517 [pii]
AID - pharmaceuticals-15-00517 [pii]
AID - 10.3390/ph15050517 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Apr 22;15(5):517. doi: 10.3390/ph15050517.